Naji Gehchan, M.D.

Naji Gehchan, M.D.

Chief Medical and Development OfficeratKyverna Therapeutics· In the 2025 proxy

Pay in FY2025Kyverna Therapeutics stock +151.3% the same year

Naji Gehchan, M.D. was paid $2.1M in FY2025 (Dec). Kyverna Therapeutics stock rose 151.3% that year.

Pay$100 in the stock at the end of FY24 → $251
Pay is from the Summary Compensation Table of each Kyverna Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kyverna TherapeuticsPublic company · 1 yr
    • Chief Medical and Development Officer2025 – Present · 1 yrStock in role +49%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?